Navigation Links
Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
Date:3/30/2009

red by the SPECT total severity score, (-256 versus +13, p=0.01). Further, patients receiving 10 or more million cells showed a trend towards improvement in ejection fraction, the percentage of blood pumped out of a ventricle with each heartbeat, (+4% versus +1%); end systolic volume (-5.7mL versus -0.1mL); and infarct size, tissue death due to loss of adequate blood supply, (-10% versus -3%) at six month follow-up. No study-related significant adverse events were reported.

"We are very encouraged that our latest findings continue to show the potential for a patient's own stem cells to reduce serious long-term complications from a heart attack," said Arshed Quyyumi, M.D., FRCP, FACC, Professor of Medicine, Cardiology, at Emory University School of Medicine and the trial's principal investigator. "This study has potentially set an important dosing threshold that offers greater protection against future down-stream adverse events, with no impact on the safety profile. Importantly, the treatment regimen is such that there is no change to our standard treatment practices. We look forward to beginning a Phase II trial."

Of the 1 million heart attacks in the U.S. each year, nearly 20% are severe enough to cause ventricular remodeling. Amorcyte's patented technologies and cGMP (current good manufacturing practices) manufacturing processes address the therapeutic and commercial challenges to post-MI stem cell treatment. Unlike other approaches, Amorcyte's technology has established cell product identity, purity, dose and potency, along with sterility and product shelf-life.

A previously published meta-analysis(1) of prior clinical trials, which included a cumulative 698 patients who received intracoronary autologous cell therapy after AMI, showed a significant improvement in ejection fraction, end systolic volumes, infarct size, reduction in subsequent MI's, and trends towards reduced deaths, admissions
'/>"/>

SOURCE Amorcyte, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
5. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
6. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
7. Neogen Reports Record Third Quarter
8. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
9. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
10. BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
11. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... The Minnesota High Tech Association ... cellular modems , platforms and application-specific remote monitoring ... for the 2014 Tekne Awards. The awards ... Convention Center on Thursday, November 13th. The Tekne ... shown superior technology innovation and leadership. , ...
(Date:9/22/2014)... and SANTA CLARA, Calif. ... (NASDAQ: WBMD ), the leading source of ... WebMD/Medscape survey that provide novel insights regarding ... aiding diagnosis and care.  Dr. Eric Topol , ... digital medicine, who serves as both Editor-in-Chief of Medscape ...
(Date:9/22/2014)... in a mouse model of pancreatic cancer identified distinct ... including significant differences from the primary tumor that may ... their study reported in the Sept. 25 issue of ... Hospital (MGH) Cancer Center identified several different classes of ... to be targets for improved treatment of the deadly ...
(Date:9/22/2014)... D.C. (PRWEB) September 22, 2014 ... Georgetown President John DeGioia on Friday renewed their ... for an additional five years to expand the ... biosecurity, nonproliferation and global climate, energy and environmental ... of an MOU originally signed in December 2009 ...
Breaking Biology Technology:NimbeLink Named Finalist for 15th Annual Tekne Awards 2NimbeLink Named Finalist for 15th Annual Tekne Awards 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2
... Mass., March 19 MacroChem,Corporation (OTC Bulletin Board: ... to the position of Chief Financial Officer, effective,immediately. ... and Vice,President, Corporate Development since joining the Company ... CFO of Bioenvision, Inc. prior to its,successful merger ...
... Years In 2008 And, Beyond, According To The Latest Research Released By ... ... the economy slides into,recession, IBISWorld today announced its list of industries with ... of the top 10 industries which IBISWorld predicts to do,well in 2008 ...
... of Standards and Technology (NIST) have set the stage ... today built from semiconductor compounds and future generations of ... upcoming paper in the Journal of the American Chemical ... of organic molecules can be assembled on the same ...
Cached Biology Technology:MacroChem Appoints David P. Luci as New CFO 2MacroChem Appoints David P. Luci as New CFO 3The Recession List - Top 10 Industries to Fly and Flop in 2008 2The Recession List - Top 10 Industries to Fly and Flop in 2008 3The Recession List - Top 10 Industries to Fly and Flop in 2008 4The Recession List - Top 10 Industries to Fly and Flop in 2008 5The Recession List - Top 10 Industries to Fly and Flop in 2008 6NIST team proves bridge from conventional to molecular electronics possible 2
(Date:9/23/2014)... -- Newest Market IPO,s and exchange ... significant investor attention with news concerning shareholder updates and new ... NXT-ID, Inc. (NASDAQ: NXTD ), Alibaba Group Holding ... MBLY ), GoPro, Inc. (NASDAQ: GPRO ) ... (NASDAQ: NXTD ) recently completed an essential round ...
(Date:9/22/2014)... ATLANTA September 23, 2014 A new American ... Supplemental Nutrition Assistance Program (SNAP), previously known as ... scores compared with income eligible non-participants. The authors ... programs aimed at enhancing the dietary quality of ... assist low-income individuals and households with the resources ...
(Date:9/22/2014)... genetic sequencing technologies continue to evolve rapidly, becoming part ... establish appropriate policies and regulatory frameworks to address potential ... policy issue of the Journal of Law, Medicine ... experts with the Center for Medical Ethics and Health ... the tools to jumpstart this process. , Experts ...
Breaking Biology News(10 mins):Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7Federal food program puts food on the table, but dietary quality could be improved 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3
... The MRSA 'superbug' evades many of the measures introduced ... organism found almost everywhere in hospital wards, according to ... Scientists from the University of Bath have shown that ... called Acanthamoeba polyphaga, which is ubiquitous in the environment ...
... cancers actually share something in common ?a molecular "signature" made ... that target key cancer genes and promote malignant growth. ... emerging class of gene regulators and may also pave the ... The study appears online in the Proceedings of the National ...
... discovered that some type of protective system goes into ... is deficient. This discovery indicates a hidden safety net ... the immune system such as AIDS. The Mayo Clinic-led ... and is reported in the early online edition of ...
Cached Biology News:MRSA use amoeba to spread, new research shows 2Common molecular 'signature' identified in solid tumors 2Common molecular 'signature' identified in solid tumors 3Infant transplant patients resist infections that kill adult AIDS patients 2Infant transplant patients resist infections that kill adult AIDS patients 3
Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
... antibody raised against a partial ... Immunogen: TOPORS (NP_005793, 98 ... recombinant protein with GST tag. ... NM_005802 ...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Biology Products: